CVRx, Inc. (CVRX)

CVRx's stock has experienced a significant decline of 46.25% over the past six months, but recently gained 12% in a week. Key events include the release of Q1 and Q2 2025 financial results, the appointment of Kevin Hykes as CEO, positive news regarding outpatient payment for Barostim, and the upcoming Q3 2025 earnings release. CMS proposed to keep the Barostim implant procedure in New Technology Ambulatory Payment Classification (APC) 1580, with an associated payment of approximately $45,000 for outpatient procedures.

There is no explicit information indicating specific calendar-based demand seasonality for CVRx, Inc.'s products and services. The broader implantable medical devices market experiences consistent growth due to the increasing prevalence of chronic conditions, an aging global population, and technological advancements. The COVID-19 pandemic negatively impacted the industry due to a reduction in elective surgeries.

CVRx, Inc. is a commercial-stage medical device company specializing in neuromodulation solutions for cardiovascular diseases. Their primary product, the Barostim Neo System, is an implantable device designed to treat heart failure and high blood pressure by stimulating baroreceptors. It is the first FDA-approved implantable device targeting the baroreflex mechanism.

CVRx has a significant market presence in the United States and Europe. The majority of revenue comes from the USA market, with a 15% increase in U.S. Heart Failure revenue in the second quarter of 2025. European revenue also increased by 19% in the second quarter of 2025, although total revenue units slightly decreased.

CVRx's brand reputation has been positively influenced by clinical validation and recognition within the medical community. Additional data supporting the long-term benefits of Barostim were published in the European Journal of Heart Failure. CVRx supported the SWIFT-HF Working Group's proposal for a heart failure device strategy published in the Journal of Cardiac Failure.

Institutional shareholders hold a significant portion of CVRx, Inc., ranging from 47% to 66.65%. Major institutional owners include Johnson & Johnson Innovation - JJDC, Inc., NEA Management Company, LLC, Vanguard Group Inc., and Blackrock, Inc. Johnson & Johnson is the largest individual shareholder, owning 29.06% of the company. Insider buying has been observed in the past six months.